findmyKOL
Clinical trialNCT02828033UnknownEarly phase 1Interventional

Rilonacept for Treatment of Autoimmune Neurosensory Hearing Loss

SponsorStanley CohenEnrollment10Autoimmune Neurosensory Hearing Loss (ANSHL)
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This study is an open label proof of concept study of rilonacept for patients with ANSHL
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Metroplex Clinical Research Center

    Dallas, Texas, United States

    Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Rilonacept →
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
1 Feb 2017
Primary completion
31 Mar 2018
Completion
31 Mar 2018
Last update posted
13 Sept 2017
Registered enrollment
10
Registry id
NCT02828033
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.